Expanded Access Remdesivir (RDV; GS-5734™)
Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™)
Sponsor: U.S. Army Medical Research and Development Command
A observational or N/A phase clinical study on Coronavirus Disease 2019, this trial is ongoing. The trial is conducted by U.S. Army Medical Research and Development Command and has accumulated 9 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
No Longer Available
-
Sep 2024 — Sep 2025 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2022 — Jul 2024 [monthly]
No Longer Available
-
May 2021 — Mar 2022 [monthly]
No Longer Available
▶ Show 4 earlier versions
-
Apr 2021 — May 2021 [monthly]
No Longer Available
Status: Available → No Longer Available
-
Jan 2021 — Apr 2021 [monthly]
Available
-
May 2020 — Jan 2021 [monthly]
Available
-
Apr 2020 — May 2020 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- U.S. Army Medical Research and Development Command
For direct contact, visit the study record on ClinicalTrials.gov .